Kelly Lauds Trump Administration for Lowering Cost of Insulin for America’s Seniors

May 26, 2020 Issues: Health Care

Washington, D.C. - Today, the U.S. Centers for Medicare and Medicaid Services (CMS) unveiled plans to lower the cost of insulin and expand coverage for diabetes treatments for seniors with Medicare Part D and Medicare Advantage drug plans. U.S. Representative Mike Kelly (R-Pa.), a member of the Congressional Diabetes Caucus and a diabetic himself, issued this statement after the announcement:

"The sky-rocketing price of insulin has caused great hardship for millions of Americans with diabetes. I applaud President Trump for fighting to lower seniors’ out-of-pocket costs and look forward to working with him to make this life-saving drug affordable for all Americans who depend on it."


1,750 Medicare Part D and Medicare Advantage plans are moving to reduce insulin co-pays to $35 per month for seniors, signaling significant buy-in to CMS’ new market-based drug payment model. Additionally, these Medicare plans will be able to cover essential services such as transportation to and from doctor’s appointments, diabetes education programs, nutritionist advice, and other treatments that support patients living with diabetes.

CMS estimates that beneficiaries who join one of these plans will save an average of $446 per year on insulin costs.

In 2019, Kelly authored H.R. 4244, the MAGIC Act, which will establish a clear and permanent approval pathway at the Food and Drug Administration (FDA) for generic insulin products via the abbreviated new drug application (ANDA) process. Generic alternatives have proven to lower the price of countless medications, and increased competition in the insulin market will lower out-of-pocket costs for all American diabietics.